Apr 11, 2022 / 07:45PM GMT
Gil Blum - Needham & Company, LLC - Analyst
Good afternoon, everybody. My name is Gil Blum, and I am a senior analyst at Needham and Company covering companies particularly in oncology space. It is my pleasure to have Paula Ragan here from X4 with me, and she will discuss X4's recent progress and clinical programs. Paula?
Paula Ragan - X4 Pharmaceuticals, Inc. - CEO & President
Thanks so much, Gil. We appreciate the chance to present at the Needham conference. Just as a reminder, I'll be making forward-looking statements. We encourage everybody to review our most recent 10-K filing for specifics around our risks and forward-looking statements.
So I'm very pleased to share the X4 story with you where we're focused on developing innovative treatments for rare diseases that are caused by a dysregulated immune system. The immune system is so critical in health and well-being. And there's several areas that we believe our once-daily oral can address and create dramatic impact favorably for patients in the US and worldwide, potentially treating over
X4 Pharmaceuticals Inc at Needham Healthcare Conference (Virtual) Transcript
Apr 12, 2022
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers